Jeff Jones
Stock Analyst at Oppenheimer
(0.84)
# 3,812
Out of 4,920 analysts
94
Total ratings
22.35%
Success rate
-18.1%
Average return
Main Sectors:
Stocks Rated by Jeff Jones
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KYMR Kymera Therapeutics | Maintains: Outperform | $56 → $53 | $42.94 | +23.43% | 5 | Jun 27, 2025 | |
| AVBP ArriVent BioPharma | Maintains: Outperform | $39 → $44 | $19.45 | +126.22% | 3 | Jun 24, 2025 | |
| YMAB Y-mAbs Therapeutics | Maintains: Outperform | $20 → $15 | $8.52 | +76.06% | 3 | May 29, 2025 | |
| CMMB Chemomab Therapeutics | Maintains: Outperform | $11 → $10 | $0.97 | +930.93% | 8 | May 16, 2025 | |
| ALMS Alumis | Maintains: Outperform | $26 → $25 | $4.20 | +495.24% | 2 | May 15, 2025 | |
| ZURA Zura Bio | Maintains: Outperform | $19 → $17 | $1.57 | +982.80% | 4 | May 9, 2025 | |
| CRVS Corvus Pharmaceuticals | Reiterates: Outperform | $15 → $17 | $4.29 | +296.27% | 5 | May 9, 2025 | |
| IMCR Immunocore Holdings | Maintains: Outperform | $85 → $86 | $32.50 | +164.62% | 2 | May 8, 2025 | |
| CRBP Corbus Pharmaceuticals Holdings | Maintains: Outperform | $60 → $56 | $8.90 | +529.21% | 9 | May 7, 2025 | |
| EVH Evolent Health | Maintains: Outperform | $28 → $18 | $9.50 | +89.47% | 4 | Jan 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $4.87 | - | 5 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $22 → $16 | $3.92 | +308.16% | 7 | Nov 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $10 → $9 | $2.58 | +248.84% | 10 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $48 → $45 | $1.73 | +2,501.16% | 6 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $14.28 | - | 4 | Jun 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Perform | n/a | $1.06 | - | 3 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $28,800 | $8.21 | +350,691.72% | 3 | May 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $3.74 | - | 2 | May 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $15 | $1.48 | +913.51% | 5 | May 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $75 | $0.68 | +10,856.90% | 2 | Mar 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $1,600 → $1,100 | $2.68 | +40,944.78% | 2 | Nov 17, 2022 |
Kymera Therapeutics
Jun 27, 2025
Maintains: Outperform
Price Target: $56 → $53
Current: $42.94
Upside: +23.43%
ArriVent BioPharma
Jun 24, 2025
Maintains: Outperform
Price Target: $39 → $44
Current: $19.45
Upside: +126.22%
Y-mAbs Therapeutics
May 29, 2025
Maintains: Outperform
Price Target: $20 → $15
Current: $8.52
Upside: +76.06%
Chemomab Therapeutics
May 16, 2025
Maintains: Outperform
Price Target: $11 → $10
Current: $0.97
Upside: +930.93%
Alumis
May 15, 2025
Maintains: Outperform
Price Target: $26 → $25
Current: $4.20
Upside: +495.24%
Zura Bio
May 9, 2025
Maintains: Outperform
Price Target: $19 → $17
Current: $1.57
Upside: +982.80%
Corvus Pharmaceuticals
May 9, 2025
Reiterates: Outperform
Price Target: $15 → $17
Current: $4.29
Upside: +296.27%
Immunocore Holdings
May 8, 2025
Maintains: Outperform
Price Target: $85 → $86
Current: $32.50
Upside: +164.62%
Corbus Pharmaceuticals Holdings
May 7, 2025
Maintains: Outperform
Price Target: $60 → $56
Current: $8.90
Upside: +529.21%
Evolent Health
Jan 24, 2025
Maintains: Outperform
Price Target: $28 → $18
Current: $9.50
Upside: +89.47%
Dec 11, 2024
Downgrades: Perform
Price Target: n/a
Current: $4.87
Upside: -
Nov 22, 2024
Maintains: Outperform
Price Target: $22 → $16
Current: $3.92
Upside: +308.16%
Nov 8, 2024
Reiterates: Outperform
Price Target: $10 → $9
Current: $2.58
Upside: +248.84%
Aug 8, 2024
Maintains: Outperform
Price Target: $48 → $45
Current: $1.73
Upside: +2,501.16%
Jun 7, 2024
Downgrades: Perform
Price Target: n/a
Current: $14.28
Upside: -
Apr 1, 2024
Reiterates: Perform
Price Target: n/a
Current: $1.06
Upside: -
May 25, 2023
Maintains: Outperform
Price Target: $28,800
Current: $8.21
Upside: +350,691.72%
May 23, 2023
Downgrades: Perform
Price Target: n/a
Current: $3.74
Upside: -
May 11, 2023
Reiterates: Outperform
Price Target: $15
Current: $1.48
Upside: +913.51%
Mar 24, 2023
Reiterates: Outperform
Price Target: $75
Current: $0.68
Upside: +10,856.90%
Nov 17, 2022
Maintains: Outperform
Price Target: $1,600 → $1,100
Current: $2.68
Upside: +40,944.78%